Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can mapping migrant networks help end neglected tropical diseases?

NCT ID NCT07707817

Disease control Sponsor: Uwemedimo Friday Ekpo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests a community-designed strategy to deliver preventive chemotherapy to mobile and migrant populations in Nigeria, who often miss treatment for neglected tropical diseases like river blindness and schistosomiasis. Researchers will work with communities to map migration patterns and set up convenient medicine distribution points. The goal is to see if this approach increases treatment coverage and brings these diseases closer to elimination.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
preventive chemotherapy medicines (ivermectin, albendazole, praziquantel) delivered through a modified mass administration strategy
What this could lead to
If successful, this approach could help eliminate neglected tropical diseases like river blindness and schistosomiasis in hard-to-reach communities.
What could go wrong
This is an implementation study, not a drug trial, so success depends on community participation and logistics. Results may not apply to other regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 5,760 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

5 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Participants will be eligible for inclusion if they: 1. Are children aged 5-14 years or adult heads of households residing in households identified as belonging to mobile or migrant populations. 2. Reside permanently or semi-permanently within the study communities 3. Have missed one or more previous rounds of onchocerciasis and/or lymphatic filariasis MDA. 4. Are willing to provide the required biological specimens and participate in interviews, surveys, and participatory workshops or discussions as required by the study protocol. 5. Provide informed consent or assent with parental/guardian consent where applicable for minors. Exclusion Criteria: Participants will be excluded if they: 1. Are temporary visitors without meaningful residence in the study communities. 2. Do not belong to the identified mobile or migrant populations targeted by the study. 3. Are unable or unwilling to provide the required biological specimens or participate in study procedures. 4. Decline informed consent or assent, or whose parent or guardian declines consent for participation. 5. Are severely ill or have medical conditions that, in the opinion of study personnel, would make participation unsafe or inappropriate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lymphatic filariasis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

filarial elephantiasis filariasis helminthiasis Infections Neglected Diseases ocular onchocerciasis onchocerciasis schistosomiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lymphatic filariasis Onchocerciasis (river blindness) Schistosomiasis Soil transmitted helminth (STH) infections

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Recruitment is done at the Household level in selected communities

    RECRUITING

    Ondo, Ondo, Taraba and Akwa Ibom, Nigeria

More trials for these conditions

Other studies related to the condition(s) this trial covers.